Matching articles for "Rebyota"
Issue 1677 · May 29, 2023 Free
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence

The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection…

Med Lett Drugs Ther. 2023 May 29; 65(1677):81-2 doi:10.58347/tml.2023.1677a
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection (CDI) in adults. Vowst is the first orally administered microbiota-based treatment to be approved for this indication. A rectally-administered live fecal microbiota-based suspension (Rebyota) was approved in 2022 for the same indication. Neither product is approved for acute treatment of CDI.
Issue 1671 · March 6, 2023
Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence

The FDA has approved Rebyota (Ferring), a rectally-administered, live fecal microbiota suspension, for prevention of additional recurrences of Clostridioides difficile infection (CDI) following antibiotic…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):35-6 doi:10.58347/tml.2023.1671b
The FDA has approved Rebyota (Ferring), a rectally-administered, live fecal microbiota suspension, for prevention of additional recurrences of Clostridioides difficile infection (CDI) following antibiotic treatment for a recurrent episode of CDI in adults. Rebyota is the first microbiome-based treatment to be approved for this indication. It is not approved for initial treatment of CDI. Fecal microbiota transplantation (FMT) has been used in patients with multiple CDI recurrences.